Ann Rheum Dis: Initial joint use of Alyson Tan and Dallanon to treat connective tissue disease-associated pulmonary hypertension (CTD-PAH)

The study was designed to assess the effectiveness of the initial combination therapy (COMB), as well as baseline characteristics and risk stratification, in the primary group of connective tissue disease-associated pulmonary hypertension (CTD-PAH) and systemic sclerosis (SSc) -PAH), as well as baseline characteristics and risk stratification in predictive outcomesthis post-mortem analysis of the Enlisant Tan and Dandara non-therapeutic pulmonary hypertension study (AMBITION) included CTD-PAH patients from the intended populationThe time to clinical failure (TtCF) was assessed based on baseline characteristics, baseline, and 16 weeks of treatment allocation and risk group (low, medium, and high)Compare TtCF between groups using the Kaplan-Meier curve and the Cox scale risk regression modelthe analysis included 216 patients (COMB, n?117; MONO, n-99)The risk of clinical failure in the COMB group was lower than in the MONO group (risk reduction: CTD-PAH 51.7%, SSc-PAH 53.7%), especially in patients with typical PAH hemodynamic parameters but no left heart disease and/or restrictive pulmonary disease characteristics at baselineIn baseline low-risk groups (uncalculated HR because there are no events in the COMB group), the baseline critical group (HR 0.519, 95% CI 0.297-0.905) and the 16-week low-risk group (HR 0.069, 95% CI 0.009-0.548), comb's clinical failure risk is lower than that of the MONO groupdemonstrated that COMB is superior to MONO in CTD-PAH patients, especially those with typical PAH hemodynamic characteristics at baselineCOMB is suitable for patients classified as low-risk and medium-critical at baseline and in follow-up to low-risk patients